• 51 minutes 43 seconds
    Turning Waste Into Fuel: The Science and Economics of Clean Energy | Wray Thorn - President and Chief Financial Officer, XCF Global

    Send us Fan Mail

    Today, on Progress, Potential, and Possibilities, we're exploring one of the most important challenges facing the global energy transition: how do we move promising clean-energy technologies beyond the laboratory and into commercially viable, large-scale industrial production?

    As governments, industries, and consumers look for ways to reduce greenhouse gas emissions, enormous attention has been directed toward electrification, batteries, hydrogen, and renewable power generation. But what about the sectors that will continue to depend on liquid fuels for the foreseeable future, including aviation, heavy transportation, and industrial applications?

    And perhaps just as importantly, how do we attract the investment, build the infrastructure, and develop the business models necessary to make cleaner fuels economically competitive?

    Joining us today is Wray Thorn, President and Chief Financial Officer of XCF Global ( Nasdaq: SAFX - https://xcf.global/ ), a U.S.-based clean fuels company focused on expanding domestic renewable fuel production through facility development, strategic acquisitions, and international licensing.

    At the center of XCF's operations is its flagship New Rise Renewables facility in Reno, Nevada, which, according to the company, produced and shipped more than 2.6 million gallons of renewable diesel through September 2026.

    Wray brings more than three decades of experience in investment management, private equity, venture capital, business development, and corporate leadership.

    Before joining XCF Global, he served as Managing Director and Chief Investment Officer for Private Investments at Two Sigma Investments, where he helped build the firm's private investment businesses, including initiatives spanning venture capital, private equity, and impact investing.

    Earlier in his career, Wray held senior investment roles at Marathon Asset Management, Fox Paine, Dubilier & Co., and Chemical Bank, now part of JPMorgan Chase.

    He is also a founder of Focus Impact Partners and Clear Heights Capital and has been deeply involved in philanthropic initiatives supporting young people, education, and economic opportunity, including leadership positions with Youth INC and Futures and Options.

    A graduate of Harvard University, Wray has spent his career at the intersection of capital, innovation, entrepreneurship, and long-term value creation.

    Today, we'll explore the science and economics of renewable fuels, the challenges of building and financing industrial-scale clean-energy infrastructure, the strategic vision behind XCF Global, and what it will ultimately take to make sustainable fuels a meaningful part of the world's energy future.

    #SustainableAviationFuel #RenewableDiesel #CleanEnergy #XCFGlobal #WrayThorn #SAF #RenewableFuels #EnergyTransition #AviationFuel #Biofuels #EnergyInnovation #CleanTechnology #EnergySecurity #Decarbonization #GreenAviation #FutureOfEnergy #SustainableEnergy #IndustrialInnovation #EnergyInfrastructure #ClimateTechnology #ProgressPotentialAndPossibilities

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    20 November 2026, 7:00 pm
  • 29 minutes 5 seconds
    When the Flu Turns Deadly: A Sister's Story of Loss and Advocacy | Irelynd McCarthy - Advocate, Families Fighting Flu

    Send us Fan Mail

    On Christmas Day in 2014, three-year-old Ayzlee McCarthy was opening presents and celebrating with her family. Four days later, she was gone. The cause wasn't an accident or a rare genetic disorder. It was influenza. Today, we're speaking with her sister about what happened, what medicine couldn't prevent, and the mission that emerged from an unimaginable loss.

    Irelynd McCarthy is a student at Drake University, pursuing studies in marketing, management, and organizational leadership, with a particular interest in nonprofit communications, advocacy, and community engagement.

    She also works with Families Fighting Flu ( https://familiesfightingflu.org/family-story/the-mccarthy-family/ ), a national nonprofit dedicated to protecting children, families, and communities from influenza through education, advocacy, and vaccination awareness.

    Through social media, digital storytelling, and public health outreach, Irelynd is helping ensure that her sister's story continues to reach families across the country.

    Today, we'll explore Ayzlee's life and the heartbreaking circumstances surrounding her death, the science of severe influenza in children, the importance and limitations of vaccination, and how one young woman is turning her family's loss into a mission to protect others.

    #Influenza #FluAwareness #IrelyndMcCarthy #AyzleeMcCarthy #FamiliesFightingFlu #FluPrevention #FluVaccine #ChildhoodInfluenza #PediatricHealth #PublicHealth #VaccineAwareness #SepsisAwareness #ChildhoodIllness #InfectiousDiseases #HealthAdvocacy #PatientAdvocacy #MedicalScience #FluSeason #ProgressPotentialAndPossibilities #IraPastor

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    19 November 2026, 10:00 pm
  • 32 minutes 36 seconds
    Why Is Colon Cancer Rising in Young Adults? New Clues from Tumor Biology | Dr. Ana Anderson, Ph.D. - Harvard Medical School / Gene Lay Institute of Immunology and Inflammation

    Send us Fan Mail

    Colorectal cancer is now the leading cause of cancer death among Americans under 50. Why is a disease traditionally associated with aging increasingly affecting younger adults? And could the answers be hiding inside the tumors themselves?

    Dr. Ana C. Anderson, PhD, ( https://anacandersonlab.com/about ) is the Albert H. Coons Professor of Neurology at Harvard Medical School and a core faculty member of the Gene Lay Institute of Immunology and Inflammation ( https://genelayinstitute.org/ ), affiliated with Brigham and Women's Hospital, Massachusetts General Hospital, and Harvard Medical School.

    Dr. Anderson is an internationally recognized immunologist whose research explores how the immune system is regulated, how immune cells interact with their surrounding tissues, and how these processes influence human diseases, including cancer and immune-mediated disorders.

    She earned her bachelor's degree in Microbiology and Immunology from the University of Miami and her PhD in Immunology from Harvard University, before building a distinguished academic career at Harvard Medical School, where she has served on the faculty for more than two decades.

    Dr. Anderson is a co-senior author of a groundbreaking new study published in Nature Medicine, conducted in collaboration with scientists at Mass General Brigham, Dana-Farber Cancer Institute, and the Broad Institute.

    By examining 189 colorectal tumors from patients spanning more than six decades of life and analyzing gene activity across more than 850,000 cells, the research team uncovered intriguing age-associated differences in tumor composition, cellular communication, and the activity of poorly understood RNA molecules.

    These findings may provide important new clues about the biology of early-onset colorectal cancer and potentially open new directions for cancer research and therapeutic development.

    Important Episode Link - 

    Nature Medicine - Oct 29, 2026 -
    Insights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas of colorectal cancer across the age continuum - 

    https://pubmed.ncbi.nlm.nih.gov/42957776/

    #ColorectalCancer #EarlyOnsetColorectalCancer #ColonCancer #CancerResearch #AnaAnderson #CancerBiology #CancerImmunology #YoungOnsetCancer #CancerPrevention #CancerTreatment #TumorMicroenvironment #SingleCellSequencing #RNAResearch #PrecisionMedicine #CancerAwareness #MedicalResearch #NatureMedicine #HarvardMedicalSchool #MassGeneralBrigham #DanaFarber #BroadInstitute #GeneLayInstitute #ProgressPotentialAndPossibilities

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    18 November 2026, 10:00 pm
  • 43 minutes 4 seconds
    Into the Unknown: The Untold Lives of America's Paramedics | Filmmaker Tom Putnam

    Send us Fan Mail

    Every day, paramedics rush toward situations the rest of us hope we'll never face. Heart attacks, horrific accidents, children in danger, families in crisis. But when the emergency ends and the ambulance drives away, who takes care of the people who have just witnessed the unimaginable? Filmmaker Tom Putnam takes us inside that extraordinary world in his powerful documentary Into the Unknown ( https://intotheunknowndoc.com/ ).

    Our guest today is Tom Putnam ( https://www.tomputnam.net/ ), an award-winning filmmaker, director, producer, and editor whose extraordinary body of work has taken audiences into some of the most challenging, dangerous, and deeply human environments imaginable.

    A graduate of the University of Southern California, where he studied Cinematic Arts and Journalism, and holding an MBA from St. Mary's University, Tom has built a distinguished career telling powerful stories about ordinary people facing extraordinary circumstances.

    His films have screened at more than 500 film festivals worldwide, including Sundance and Cannes, and have received more than 50 major awards, including recognition at the Tribeca Film Festival, SXSW, and the Independent Spirit Awards.

    His acclaimed documentary Burn, which followed firefighters on the front lines in Detroit, offered an unflinching look at courage, sacrifice, and survival in one of America's most challenging urban environments. He later returned to that world with Burn X, exploring how the lives of those firefighters had evolved over the intervening decade.

    His other notable projects include the acclaimed documentary Marwencol, The United States of Insanity, and the feature film The Dark Divide, starring David Cross and Debra Messing.

    Tom now turns his lens toward another extraordinary group of first responders in his latest documentary, Into the Unknown, executive produced by Steve Buscemi, along with Randolph Mantooth and Kevin Tighe, the iconic stars of the television series Emergency!

    Filmed over the course of a year across multiple American communities, Into the Unknown takes viewers inside the ambulances, emergency scenes, and personal lives of paramedics who confront life-and-death situations every day, often under unimaginable pressure.

    But this is much more than a film about emergency medicine. It is a deeply human exploration of compassion, resilience, psychological trauma, sacrifice, and the personal price paid by those who dedicate their lives to saving others.

    With the film arriving on digital platforms December 4, Tom joins us to discuss the remarkable people behind the uniform, the challenges confronting America's emergency medical services system, and what he hopes audiences will understand about the men and women who answer the call when the rest of us need them most.

    #IntoTheUnknown #TomPutnam #Paramedics #EMS #EmergencyMedicalServices #FirstResponders #EmergencyMedicine #DocumentaryFilm #SteveBuscemi #RandolphMantooth #EmergencyTV #MentalHealthAwareness #HealthcareHeroes #LifeSavingHeroes #BurnDocumentary #HealthcareInnovation #ProgressPotentialAndPossibilities #IraPastor #PPPpodcast

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    13 November 2026, 8:00 pm
  • 43 minutes 59 seconds
    The Next Gold Rush? Mining Valuable Metals From Electronic Waste | Jeet Basi, President and CEO, Modern Mining

    Send us Fan Mail

    What if the next great gold mine isn't buried beneath the Earth - but sitting inside the old smartphones, computers, and circuit boards we've already thrown away?

    Today, we're joined by Jeet Basi, President and CEO of Modern Mining ( https://modernmining.com/ ), a resource recovery company focused on extracting valuable metals from electronic waste. Modern Mining just went public and began trading on the NYSE American under the ticker symbol “MDRN” on November 13, 2026.

    Using proprietary water-based processing technologies, Modern Mining aims to recover precious and commodity metals, including gold, palladium, silver, copper, and potentially 30 additional metals. By transforming discarded electronics into valuable resources, the company is developing an alternative to traditional mining.

    Jeet brings nearly 20 years of experience in mining, mineral processing, project development, and strategic advisory roles. Before joining Modern Mining, he was a principal consultant at SVK Metrix and held technical leadership positions at Newmont, Goldcorp, and Teck Resources. He holds a Bachelor of Applied Science in Mining and Mineral Process Engineering from the University of British Columbia, with a minor in Commerce.

    In this interview, we explore how traditional mining works, the opportunity in electronic waste, the technology and economics behind recovering valuable metals, and whether urban mining could become a meaningful part of the world's future metals supply chain.

    Learn more: https://modernmining.com/

    #ModernMining #MDRN #JeetBasi #UrbanMining #ElectronicWaste #EWaste #GoldRecovery #PreciousMetals #CriticalMinerals #MineralProcessing #MiningInnovation #CircularEconomy #SustainableMining #MetalRecycling #ResourceRecovery #GoldMining #CopperMining #Metallurgy #GreenTechnology #ArtificialIntelligence #AIInfrastructure #DataCenters #SupplyChainSecurity #FutureOfMining #CleanTechnology #Innovation #ProgressPotentialAndPossibilities #IraPastor

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    13 November 2026, 5:00 pm
  • 54 minutes 20 seconds
    The Future of Emergency Medicine: Can We Fix the System? | Dr. Randy Pilgrim, MD, FACEP, FAAFP - Enterprise Chief Medical Officer, SCP Health

    Send us Fan Mail

    Modern emergency medicine can do things that would have seemed almost unimaginable a generation ago. We can diagnose faster, treat critical illness more effectively, and save lives that once would have been lost. Yet emergency departments are overcrowded, patients are boarding in hallways, clinicians are under enormous pressure, and the cost of care keeps rising. How can medicine keep advancing while the system delivering it struggles? Today, we're going to explore that question with someone who has spent decades on the front lines of emergency medicine.

    Dr. Randy Pilgrim, MD, FACEP, FAAFP ( https://www.scphealth.com/meet-dr-randy-pilgrim/ ) is Enterprise Chief Medical Officer at SCP Health, where he provides executive oversight and strategic direction for clinical operations. 

    Dr. Pilgrim has more than 30 years of experience as an emergency physician and a long track record of leadership in clinical operations, health policy, and physician advocacy.

    He has dedicated his career to improving care for both patients and clinicians, with a particular focus on developing sustainable health care models that balance quality, accessibility, and cost. He is also an experienced educator and mentor who has been recognized twice as Speaker of the Year by the American College of Emergency Physicians ( https://www.acep.org/edda/faculty-profiles/profile-pilgrim ).

    Today, we'll discuss what emergency departments reveal about the state of American health care, how we can move beyond medical breakthroughs to improve the delivery of care, and what needs to change in clinical practice, payment models, and public policy to build a healthier and more sustainable future.

    #EmergencyMedicine #Healthcare #HealthcareInnovation #EmergencyCare #HealthcarePolicy #PatientCare #HealthSystems #MedicalInnovation #PhysicianBurnout #RuralHealthcare #HealthcareCosts #NoSurprisesAct #SCPHealth #ProgressPotentialAndPossibilities

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    13 November 2026, 12:00 pm
  • 39 minutes 56 seconds
    Reinventing Tradition: How Tchotchke Is Reimagining Jewish Design | Adam and Anna Paskow, Co-Founders, Tchotchke

    Send us Fan Mail

    What happens when centuries-old Jewish traditions meet modern industrial design? Can reinventing the objects we use actually help preserve the traditions they represent?

    Today, we're going to explore a fascinating intersection of entrepreneurship, industrial design, branding, and cultural tradition - and how two entrepreneurs are reimagining something that has been part of Jewish life for centuries.

    Joining us are Adam and Anna Paskow, the husband-and-wife team behind Tchotchke ( https://www.shoptchotchke.com/ ), a New York-based design company bringing a fresh, contemporary perspective to traditional Jewish ceremonial objects, known as Judaica.

    Their story began with a rather simple observation. When Adam and Anna received a traditional menorah as a wedding gift, they appreciated its significance and sentiment, but felt that its design didn't really reflect their personal aesthetic or the way they wanted to furnish their home. They began wondering whether there was an opportunity to rethink an entire category of products - creating meaningful Jewish objects that could bridge the gap between traditional mass-market Judaica and expensive, gallery-quality art.

    Adam brings an extensive background in industrial design and product development. He previously served as Director of Industrial Design at BuzzFeed, where he led product development for its Tasty brand, and has spent much of his career translating creative concepts into tangible, manufacturable products.

    Anna brings a complementary background in brand strategy, marketing, and organizational development, having held leadership positions at companies including WeightWatchers, theSkimm, and Managed by Q. She has extensive experience building brands, developing customer relationships, and helping organizations communicate their identity and purpose.

    Together, they launched Tchotchke in 2022, initially developing prototypes for contemporary menorahs and subsequently expanding into a broader collection of Judaica, including Shabbat candlesticks, mezuzahs, and other objects that combine modern aesthetics with traditional meaning.

    Their products have gained recognition in the design and retail world, with distribution through retailers such as Nordstrom and Zola, as well as museum shops including The Jewish Museum in New York and the Skirball Cultural Center in Los Angeles.

    And there's a bigger story here than simply creating beautiful products. It's about how we preserve cultural traditions, how we make them relevant to younger generations, and how entrepreneurship and creativity can help keep those traditions alive.

    #ProgressPotentialAndPossibilities #Tchotchke #ReinventingTradition #Judaica #JewishDesign #JewishCulture #JewishHeritage #JewishIdentity #JewishTradition #LDorVDor #Hanukkah #Menorah #Shabbat #JewishEntrepreneurs #Entrepreneurship #IndustrialDesign #ProductDesign #ModernJudaica #DesignInnovation #FamilyTraditions #CulturalHeritage #SmallBusiness #JewishPride #JewishInnovation

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    12 November 2026, 9:00 am
  • 58 minutes 5 seconds
    What If GPS Goes Dark? AI, Quantum Sensing & the Future of Navigation | Luca Ferrara - General Manager, Navigation, SandboxAQ

    Send us Fan Mail

    What happens when GPS goes dark?

    No satellites. No reliable positioning signals. And an aircraft still needs to know exactly where it is.

    What if the answer has been hiding in the Earth's magnetic field all along?

    Luca Ferrara is General Manager of Navigation at SandboxAQ ( https://www.sandboxaq.com/ ), a pioneering technology company working at the intersection of artificial intelligence, advanced sensing, and quantum science.

    Luca leads the development and commercialization of AQNav, an innovative navigation technology that combines highly sensitive magnetic sensors, artificial intelligence, and geophysical mapping to help aircraft determine their position without relying on GPS.

    The technology has been flight-tested aboard military and civilian aircraft, including U.S. Air Force C-17 transport aircraft, and is being explored for applications ranging from commercial aviation to unmanned autonomous systems.

    Luca's own professional journey is equally interesting. After studying international economics at Boston College, he began his career in financial markets, working in derivatives at UBS and Goldman Sachs. He subsequently earned his MBA from the University of Chicago Booth School of Business, moved into technology strategy at Google, and became involved in an ambitious navigation moonshot within Alphabet's innovation ecosystem.

    Today, he leads a team working to translate sophisticated physics, artificial intelligence, and advanced sensing into practical technologies that could fundamentally reshape how machines navigate our world.

    We explore the science of magnetic navigation, what makes it different from GPS, the role of AI and quantum sensing, the challenges of deploying these technologies in real-world aircraft, and what this emerging field could mean for the future of autonomous systems.

    #SandboxAQ #AQNav #LucaFerrara #QuantumNavigation #QuantumSensing #ArtificialIntelligence #AI #GPS #GPSJamming #GPSSpoofing #NavigationTechnology #MagneticNavigation #QuantumTechnology #AerospaceInnovation #AutonomousSystems #AviationTechnology #NationalSecurity #DefenseTechnology #FutureOfFlight #EmergingTechnology #MachineLearning #SensorFusion #Geophysics #ResilientNavigation #ProgressPotentialAndPossibilities

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    12 November 2026, 9:00 am
  • 35 minutes 39 seconds
    Beyond the Prescription: How Science Shapes Better Patient Care - Dr. Tim Holt, DNP, PhD, MBA - Regional Medical Director, Collegium Pharmaceutical

    Send us Fan Mail

    Finding the right treatment isn't simply about choosing a medication. It's about understanding the patient, the condition, the risks, and what success actually looks like in everyday life. That's particularly challenging when we're talking about ADHD and and neuropsychiatric care.

    ADHD affects attention, impulse control, executive functioning, and everyday life. Yet the journey from recognizing symptoms to receiving an accurate diagnosis and finding an effective treatment can be complicated. Questions about access, medication, individual responses, and the broader support patients need remain central to the conversation.

    Dr. Tim Holt, DNP, PhD, MBA, is a board-certified psychiatric-mental health nurse practitioner and Regional Medical Director at Collegium Pharmaceutical ( https://www.collegiumpharma.com/ ). Tim brings a distinctive combination of experience to this discussion, having worked in clinical care, served in a supervisory public health role at the FDA, and spent years in medical affairs and scientific engagement within the pharmaceutical industry.

    Today, Tim leads and mentors medical science liaison teams, helping connect emerging scientific evidence, clinical expertise, and the needs of healthcare professionals.

    We' explore what clinicians and patients need from today's ADHD treatment landscape, where gaps remain between scientific evidence and everyday care, and how healthcare professionals can build careers beyond direct patient care while continuing to make a difference.

    Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

    With a portfolio of differentiated ADHD medications and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.

    #ADHD #ADHDTreatment #MentalHealth #Psychiatry #Neuroscience #ChronicPain #PainManagement #OpioidSafety #OpioidCrisis #PainMedicine #ClinicalCare #NursePractitioner #MedicalScience #PharmaceuticalInnovation #PatientOutcomes #HealthcareInnovation #MedicalResearch #ProgressPotentialAndPossibilities

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    10 November 2026, 8:00 pm
  • 34 minutes 40 seconds
    Can Nuclear Power Go Small? Inside Hadron Energy's Microreactor | Sam Gibson - Founder and CEO, Hadron Energy

    Send us Fan Mail

    Nuclear power has a scale problem: conventional plants are enormous, expensive projects that can take years to build. Hadron Energy wants to take a different approach with a factory-manufactured, 10-megawatt light-water microreactor. But can a smaller reactor actually mean lower costs, simpler deployment and credible safety? 

    Sam Gibson is Founder and CEO of Hadron Energy ( https://www.hadronenergy.com/ ), a company developing the Halo Micro-Modular Reactor, a proposed 10-megawatt-electric light-water nuclear reactor designed to provide continuous, carbon-free power for applications such as AI data centers, industrial facilities, and remote infrastructure.

    Sam is a mechanical engineer and a member of the Forbes 30 Under 30 Class of 2026. His work focuses on bringing nuclear engineering and manufacturing principles together to rethink how reliable energy can be delivered.

    We explore what distinguishes microreactors from conventional nuclear plants, why Hadron is betting on established light-water technology rather than alternative reactor designs, and why AI is creating new opportunities for nuclear power. We'll also examine the realities of nuclear safety, regulation, construction costs, fuel supply, and the path from a factory-built design to commercial deployment.

    And we’ll answer a fundamental question - Can smaller, standardized nuclear reactors help power our increasingly electrified world - and do they offer a practical way to bring new nuclear capacity online faster?

    #NuclearEnergy #Microreactors #SmallModularReactors #AdvancedNuclear #NuclearPower #AIDataCenters #EnergyInnovation #CleanEnergy #EnergySecurity #NuclearEngineering #Uranium #USEnergy #FutureOfEnergy #ArtificialIntelligence #ProgressPotentialAndPossibilities

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    30 October 2026, 8:00 pm
  • 45 minutes 35 seconds
    Can We Build Better Biotech Companies to Deliver Better Medicines? | Dr. Stella Vnook, Ph.D. - Founding and Managing Partner, AVIVA Ventures

    Send us Fan Mail

    The world doesn't have a shortage of promising medical discoveries. The real challenge is turning those discoveries into safe, effective, accessible treatments. What separates a breakthrough idea from a successful therapy? How could AI change the economics of drug development? And can regenerative medicine move healthcare beyond managing disease toward restoring damaged tissue? Today, we're tackling these questions with pharmaceutical executive and biotech entrepreneur Dr. Stella Vnook.

    Dr. Stella Vnook is a pharmaceutical and biotechnology executive, serial entrepreneur, and healthcare innovator with more than 25 years of experience spanning drug development, commercialization, strategic partnerships, and company building.

    A Temple University School of Pharmacy alumna, Dr. Vnook is being recognized with the university's Pharmaceutical Innovation Award as Temple celebrates its 125th anniversary - an honor recognizing her contributions to healthcare innovation.

    Over the course of her career, Dr. Vnook spent nearly 14 years at Merck in roles spanning pharmaceutical marketing, managed markets, and corporate strategy, before moving into global pharmaceutical technology and commercialization leadership at Catalent. She subsequently took on executive leadership and company-building roles across a range of biotechnology ventures, including oncology, immunotherapy, and advanced drug-delivery technologies.

    Today, Dr. Vnook is the founding and managing partner of AVIVA Ventures, a life-sciences venture studio integrating AI into the process of building and transforming biotech and pharmaceutical companies. She is also the founder, president, and CEO of Oral BioLife ( https://oralbiolife.com/ ), which is developing regenerative technology intended to stimulate bone regeneration in periodontal disease, and she has served as CEO of companies working on advanced cell therapies and drug-delivery platforms.

    Dr. Vnook's experience spans the scientific, operational, financial, and commercial sides of healthcare innovation - including fundraising, strategic licensing, market access, and the challenge of bringing new technologies from early research toward clinical and commercial application.

    Today, we'll discuss what it takes to build successful biotech companies, where regenerative medicine could take us, how AI might change the business of drug development, and what it will take to ensure that scientific breakthroughs ultimately translate into better outcomes for patients.

    #StellaVnook #OralBioLife #RegenerativeMedicine #BoneRegeneration #Biotechnology #DrugDevelopment #PharmaceuticalInnovation #AIinHealthcare #DrugDiscovery #Biotech #PrecisionMedicine #HealthcareInnovation #PeriodontalDisease #DentalHealth #ProgressPotentialAndPossibilities

    Art Is Not a Thing
    From media art to digital activism: art as critical inquiry and world-building.

    Listen on: Apple Podcasts   Spotify

    Support the show

    29 October 2026, 11:00 am
  • More Episodes? Get the App